Two popular diabetes drugs have been under scrutiny in the past few years for the adverse effects it has on its patients. The drugs are Avandia (generic name rosiglitazone) and Actos (generic name pioglitazone).
In previous studies, the risks of heart attack or cardiac failure or death from either resulted in the deaths of about four percent of the total diabetic population using rosiglitazone or pioglitazone. [click to continue…]
{ 0 comments }












